Assessing the impact of PD-1/PD-L1 inhibitors on health and budget in Belgium

被引：0
|
作者：
van Bavel, J. [1 ]
Lucherini, S. [2 ]
Vermeersch, S. [3 ]
Abreu, A. Bento [3 ]
Davies, N. [2 ]
Okhuoya, P. [2 ]
Pellisier, J. [4 ]
Roediger, A. [3 ]
机构：
[1] Merck USA, Charlotte, NC USA
[2] Adelphi Values UK, London, England
[3] MSD Belgium, Brussels, Belgium
[4] Merck USA, Chicago, IL USA
来源：
EUROPEAN JOURNAL OF PUBLIC HEALTH | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：439 / 439
页数：1
相关论文
共 50 条
  • [41] ESTIMATING THE ECONOMIC AND HEALTH IMPACT OF THE PD-1/PD-L1 INHIBITOR CLASS IN FINLAND
    Lehto, P.
    Suvanto, T.
    Aro, M.
    Normand, R.
    Nagda, N.
    Lucherini, S.
    VALUE IN HEALTH, 2020, 23 : S458 - S458
  • [42] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [43] Photodynamic Therapy enhances the Effect of PD-1/PD-L1 Inhibitors
    Erhard, Daniela
    AKTUELLE DERMATOLOGIE, 2019, 45 (07) : 316 - 316
  • [44] PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
    Zhang, Ke
    Kong, Xiangyi
    Li, Yuan
    Wang, Zhongzhao
    Zhang, Lin
    Xuan, Lixue
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] ESTIMATING THE ECONOMIC AND HEALTH IMPACT OF THE PD-1/PD-L1 INHIBITOR CLASS IN BULGARIA
    Dimitrova, M.
    Todorov, S.
    Djambazov, S.
    Slavchev, G.
    Swales, O.
    Hughes, R.
    Nagda, N.
    Lucherini, S.
    VALUE IN HEALTH, 2020, 23 : S451 - S451
  • [46] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [47] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Cheng, Chao
    Zhuge, Lingdun
    Xiao, Xin
    Luan, Siyuan
    Yuan, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Shen, Xian
    Zhao, Bin
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [49] The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis
    Kotecha, Rupesh
    Kim, Joseph M.
    Miller, Jacob A.
    Juloori, Aditya
    Chao, Samuel T.
    Murphy, Erin S.
    Peereboom, David M.
    Mohammadi, Alireza M.
    Barnett, Gene H.
    Vogelbaum, Michael A.
    Angelov, Lilyana
    Suh, John H.
    Ahluwalia, Manmeet S.
    NEURO-ONCOLOGY, 2019, 21 (08) : 1060 - 1068
  • [50] Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients
    Kyung-In Joung
    Jong Hwa Song
    Kangho Suh
    Seung-Mi Lee
    Ji Hyun Jun
    Taehwan Park
    Dong Churl Suh
    BioDrugs, 2021, 35 : 61 - 73
12345